Global Ambition: ABL Texcell Targets US and Asia in Strategic Vela Buyout

WOIPPY, France – September 21, 2026 – In the rapidly evolving landscape of 2026, the life sciences sector is undergoing a profound structural realignment. The era of pandemic-driven windfall revenues has firmly closed, leaving diagnostic developers with a stark mandate: consolidate, vertically integrate, and scale globally, or risk obsolescence. Today, a French mid-cap diagnostic firm demonstrated exactly how to execute this mandate.

ABL Texcell Diagnostics, a company specializing in molecular diagnostic solutions, alongside its parent entity Advanced Biological Laboratories S.A. (ABL), announced the signing of a non-binding letter of intent to acquire 100% of Vela Operations Singapore Pte. Ltd. and Vela Diagnostics USA Inc. The target assets, currently held by VDH Holding Pte. Ltd., represent the operational crown jewels of the Vela Group.

If finalized, this transaction will instantly transform the Euronext Paris-listed company from a regionally focused European developer into a multinational player with proprietary manufacturing and commercial infrastructure across North America and the Asia-Pacific.

"This project is a natural continuation of the exclusive distribution agreement with Vela Diagnostics for EMEA. Having built the commercial foundations of our cooperation, we now plan to take the next step by integrating strategic activities in Singapore and the United States," said Dr. Chalom Sayada, Chairman and CEO of ABL Texcell Diagnostics.

The Phased Takeover Playbook

In my daily tracking of corporate strategies, I rarely see cross-border acquisitions executed with such disciplined risk mitigation. ABL Texcell did not rush into a speculative buyout; instead, it deployed a masterclass in phased integration.

The groundwork for this acquisition was laid over two years of deepening operational ties. In April 2024, an ABL affiliate entered a New Jersey logistics and warehousing pact with Vela USA. By July 2025, ABL had secured an exclusive EMEA distribution agreement for Vela’s product line. Rather than passively distributing, ABL aggressively integrated. By November 2025, the French firm had assumed direct European reagent supply logistics, absorbed European staff from its partner, and automated its proprietary DeepChek-HIV software onto Vela’s hardware.

This "try-before-you-buy" approach yielded quantifiable results, generating a proven €1.0 million annualized revenue run-rate from the EMEA distribution alone by mid-2026. Only after verifying the commercial synergies and technical compatibility did the consortium execute the letter of intent this September. This phased model drastically reduces the post-merger integration risks that typically plague mid-market medtech transactions.

Acquiring the Sentosa Edge and Global Footprint

To understand the strategic value of this proposed acquisition, one must look beneath the corporate restructuring and examine the technological assets involved. The target company brings highly coveted, automated capabilities to ABL Texcell’s portfolio, centered around the Sentosa integrated molecular workflow.

The Sentosa platform is engineered to combine both real-time PCR (qPCR) and Next-Generation Sequencing (NGS) workflows onto a single robotic automated front-end. This includes a proprietary liquid handling workstation and a dedicated sequencer. Crucially, the target holds significant regulatory pedigree. In 2019, the U.S. FDA granted De Novo marketing authorization for its HIV-1 Genotyping Assay, making it one of the first commercially available NGS-based diagnostic tests authorized for detecting HIV-1 drug-resistant mutations.

By acquiring the Singapore operations, ABL Texcell secures an ISO-certified global manufacturing and instrument assembly hub. This facility not only allows the French firm to capture full OEM industrial gross margins—bypassing typical 20% to 35% distributor fees—but it also serves as a critical regulatory and commercial gateway into Southeast Asian markets like Malaysia, Australia, and Thailand.

Simultaneously, the acquisition of the USA division provides a ready-made commercial beachhead in Fairfield, New Jersey. Equipped with a CLIA-certified service laboratory, this U.S. footprint offers an immediate channel to directly market ABL’s Nadis electronic medical record system and CDL Pharma clinical research services to American healthcare providers.

"The proposed acquisition of Vela Operations Singapore and Vela Diagnostics USA would give ABL Texcell Diagnostics a significantly strengthened international footprint, directly covering EMEA, Asia-Pacific and the United States," Dr. Sayada added. "It would allow us to bring together complementary technological, industrial, regulatory and commercial capabilities within a single international platform, in an industry that requires consolidation."

Navigating Post-Pandemic Consolidation

Dr. Sayada’s nod to industry consolidation points to a broader macroeconomic reality. Mid-tier diagnostic developers are currently squeezed between two formidable forces: mega-cap industry giants and stringent new regulatory frameworks.

The European In Vitro Diagnostic Regulation (IVDR), which reclassified the vast majority of IVD tests into higher notified-body-assessed risk classes, has created a massive compliance bottleneck. Smaller specialty assay makers are facing prohibitive re-certification costs, estimated to be up to 60% higher per assay family. By combining ABL’s specialized virology and genotyping assays with its new automated hardware, the unified company can establish a fully IVDR-compliant automated HIV sequencing solution by 2027.

Furthermore, the scale achieved through this acquisition provides a necessary defensive moat. Mid-sized players must offer comprehensive, automated, and syndromic testing solutions to win hospital laboratory tenders against diversified giants like Roche Diagnostics, Abbott, and bioMérieux. The integration of proprietary assays directly into the factory-programmed software of platforms sold globally achieves exactly this level of competitive sophistication.

Financial Mechanics and Future Trajectory

The financial engineering required to execute this deal without severely diluting shareholders is equally noteworthy. ABL Texcell Diagnostics enters these negotiations from a position of renewed financial strength. The company’s market capitalization hovers around €40 million, supported by a fiscal year 2025 revenue jump to €6.95 million and a striking 246% year-over-year increase in net income. The momentum has continued into 2026, with first-half revenues surging to €5.42 million.

Despite this strong operational cash flow, funding the acquisition of international manufacturing and commercial subsidiaries requires structured capital. The explicit inclusion of the parent company, Advanced Biological Laboratories S.A., as a co-signatory on the letter of intent suggests a sophisticated consortium model. This structure likely involves parent equity contributions or vendor earn-out notes tied to commercial milestones, thereby protecting public shareholders from excessive equity dilution.

Additionally, the recent shareholder vote on September 17 to maintain the company’s listing on the regulated market of Euronext Paris Compartment B—rejecting a transfer to Euronext Growth—preserves access to broader institutional capital and bond markets. This strategic financial positioning ensures the company has the liquidity levers necessary to finalize the transaction.

While the letter of intent remains non-binding and subject to customary due diligence, the strategic intent is unmistakable. The French diagnostics developer is no longer content with being a specialized regional player. By methodically absorbing international infrastructure, the company is engineering a vertically integrated, global platform uniquely suited for the rigorous demands of the 2026 healthcare landscape.